Managing patients who experience 15 or more headache days per month requires effective evidence-based strategies. A recent systematic review evaluates several chronic migraine prophylaxis medications to determine their clinical efficacy and patient tolerability. This extensive review synthesized data from 43 randomized controlled trials involving over 14,000 participants.

Efficacy of Chronic Migraine Prophylaxis Medications

The study found that CGRP-targeted therapies, including eptinezumab, erenumab, fremanezumab, galcanezumab, and atogepant, significantly reduce monthly migraine days. Specifically, these agents reduced migraine frequency by approximately two days compared to placebo. Conversely, researchers noted that rimegepant probably has no effect on preventing chronic migraine, despite its utility in other settings.

Furthermore, the certainty of evidence for these newer therapies is generally high to moderate. While botulinum toxin slightly reduces monthly headache days, it also carries a higher risk of discontinuation due to adverse events. Consequently, clinicians must balance potential relief with the likelihood of treatment adherence. Additionally, evidence for older medications like topiramate, valproate, and propranolol remains limited for chronic cases. Most studies on these older agents carried a high risk of bias. Therefore, CGRP-targeted biologics currently offer a more reliable evidence base for patients with frequent attacks.

Selecting Chronic Migraine Prophylaxis Medications

When selecting a therapy, physicians should consider individual patient profiles and the risk of dropout. For instance, galcanezumab may actually reduce all-cause dropout rates compared to placebo. However, traditional oral preventatives still play a role in certain clinical scenarios despite the data gaps identified in this review. Most calcitonin gene-related peptide-targeted therapies are probably effective, marking a significant advancement in chronic migraine management.

Frequently Asked Questions

Which medications are most effective for chronic migraine prevention?

According to high-certainty evidence, CGRP-targeted therapies such as erenumab, eptinezumab, and atogepant are among the most effective for reducing monthly migraine days in adults.

Is botulinum toxin better than CGRP inhibitors for migraine?

While botulinum toxin provides some reduction in headache days, the review suggests it may lead to more frequent discontinuation due to side effects compared to newer CGRP-targeted options.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Khalili M et al. Effectiveness and Tolerability of Pharmacologic Prophylaxis for Chronic Migraine : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2026 May 05. doi: 10.7326/ANNALS-25-02221. PMID: 42081823.


2. Ailani J, et al. The American Headache Society Consensus Statement: Update on Integrating New Migraine Therapies Into Clinical Practice. Headache. 2024;64(6):635-657.


3. Mistry H, et al. Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis. J Headache Pain. 2023;24(1):164.